0
Abstract Views
0
PDF Download
Case-Study

A case report Cerebral Toxoplasmosis Therapy in A Patient with Human Immunodeficiency Virus

Livia Aurellia Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia, Indonesia Correspondence liviaaurellia@gmail.com
,
Rani Nur Badriyah Pharmacy Department, Saiful Anwar Regional Public Hospital, Malang, Indonesia, Indonesia Correspondence Syahida.girl410@gmail.com
,
Reta Anggraeni Widya Pharmacy Department, Saiful Anwar Regional Public Hospital, Malang, Indonesia, Indonesia Correspondence Retaawidya@gmail.com
,
Jainuri Erik Pratama Pharmacy Department, Dr. Kariadi Central General Hospital, Semarang, Indonesia, Indonesia Correspondence erik.rsdk@gmail.com
,
Fauna Herawati Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia, Indonesia Correspondence fauna@staff.ubaya.ac.id
,
Antonius Adji Prayitno Setiadi Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia, Indonesia Correspondence adji_ps@staff.ubaya.ac.id
,
Marisca Evalina Gondokesumo Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia, Indonesia Correspondence marisca@staff.ubaya.ac.id
Pages 188-194
Browse this journal

Abstract

: Toxoplasma infection or toxoplasmosis is an infectious disease caused by the parasite Toxoplasma gondii. Toxoplasma gondii infection of the central nervous system occurs in patients with immunodeficiency. The recommended first-line therapy is pyrimethamine + sulfadiazine + leucovorin, however, due to the unavailability of pyrimethamine, the alternative therapy that can be used is trimethoprim + sulfamethoxazole. We present a case of cerebral toxoplasmosis in a male patient, 31 years old, with HIV disease, admitted to the hospital with the main complaint, namely gradual disorder of consciousness (DOC) or decreased consciousness six days before entering the hospital. Initially, the patient looked confused. However, over time, the patient becomes increasingly challenging to communicate with. The patient is post-status general motor onset tonic seizure. The patient has had diarrhea for two months with black stools. The patient also had a fever. The patient received a combination therapy of Clindamycin 4x600mg and Cotrimoxazole 2x960mg. The combination of Clindamycin and Cotrimoxazole is recommended as an alternative therapy, but further research is needed regarding the outcome of therapy.

There is no Figure or data content available for this article

References

  • 1. Jones JL, Kruszon-Moran D, Rivera HN, Price C, Wilkins PP. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135-1139. doi:10.4269/ajtmh.14-0013
  • 2. Dian S, Ganiem AR, Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog Glob Health. 2023;117(1):14-23. doi:10.1080/20477724.2022.2083977
  • 3. Vidal JE. HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care. 2019;18:2325958219867315. doi:10.1177/2325958219867315
  • 4. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965-1976. doi:10.1016/S0140-6736(04)16412-X
  • 5. Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4(10):1363-1379. doi:10.2217/fmb.09.89
  • 6. Kato K. How does Toxoplasma gondii invade host cells? J Vet Med Sci. 2018;80(11):1702-1706. doi:10.1292/jvms.18-0344
  • 7. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol. 2012;34(6):793-813. doi:10.1007/s00281-012-0339-3
  • 8. El Saftawy EA, Shash RY, Aboulhoda BE, et al. Insights into immunopathology and triggering of apoptosis in chronic cerebral toxoplasmosis using murine models. Trop Biomed. 2021;38(2):53-62. doi:10.47665/tb.38.2.037
  • 9. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643-1648. doi:10.1056/NEJM199212033272306
  • 10. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211-222. doi:10.1093/clinids/15.2.211
  • 11. Augustine SAJ, Eason TN, Simmons KJ, et al. Rapid, cost-effective, and simultaneous detection of anti-Toxoplasma IgG, IgM, and IgA antibodies by use of very small serum volumes. J Clin Microbiol. 2016;54(8):1961-1966. doi:10.1128/JCM.00913-16
  • 12. Osunkalu VO, Akanmu SA, Ofomah NJ, et al. Seroprevalence of Toxoplasma gondii IgG antibody in HIV-infected patients at the Lagos University Teaching Hospital. HIV AIDS (Auckl). 2011;3:101-105. doi:10.2147/HIV.S15532
  • 13. Anselmo LMP, Vilar FC, Lima JE, Yamamoto AY, Bollela VR, Takayanagui OM. Usefulness and limitations of polymerase chain reaction in the etiologic diagnosis of neurotoxoplasmosis in immunocompromised patients. J Neurol Sci. 2014;346(1-2):231-234. doi:10.1016/j.jns.2014.08.034
  • 14. Alfonso Y, Fraga J, Jimenez N, et al. Detection of Toxoplasma gondii in cerebrospinal fluid from AIDS patients by nested PCR and rapid identification of type I allele at B1 gene by RFLP analysis. Exp Parasitol. 2009;122(3):203-207. doi:10.1016/j.exppara.2009.03.009
  • 15. Zawadzki R, Modzelewski S, Naumowicz M, et al. Evaluation of imaging methods in cerebral toxoplasmosis. Pol J Radiol. 2023;88:e389-e398. doi:10.5114/pjr.2023.130981
  • 16. Graham AK, Fong C, Naqvi A, Lu JQ. Toxoplasmosis of the central nervous system: manifestations vary with immune responses. J Neurol Sci. 2021;420:117223. doi:10.1016/j.jns.2020.117223
  • 17. Chandra FA. Tata laksana ensefalitis toksoplasma pada penyandang HIV. Cermin Dunia Kedokt. 2022;49(9):504-507. doi:10.55175/cdk.v49i9.2034
  • 18. Sarongku T, Ariswanda G, Sumada I, Wiratni N, Widyadharma I. Clindamycin as single therapy for cerebral toxoplasmosis HIV in the history of sulfa allergy: a case report. Int J Surg Med. 2019;5:1. doi:10.5455/ijsm.case-report-neuroinfection
  • 19. Mohammadi K, Khalili H, Jafari S, Yaribash S. Treatment of toxoplasmic encephalitis with the combination of clindamycin plus azithromycin in an HIV-infected patient: a case report. Clin Case Rep. 2021;9(5):e04045. doi:10.1002/ccr3.4045
  • 20. Madi D, Achappa B, Rao S, Ramapuram JT, Mahalingam S. Successful treatment of cerebral toxoplasmosis with clindamycin: a case report. Oman Med J. 2012;27(5):411-412. doi:10.5001/omj.2012.100
  • 21. Patil HV, Patil VC, Rajmane V, Raje V. Successful treatment of cerebral toxoplasmosis with cotrimoxazole. Indian J Sex Transm Dis AIDS. 2011;32(1):44-46. doi:10.4103/0253-7184.81255
  • 22. Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992;11(2):125-130. doi:10.1007/BF01967063
  • 23. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1998;42(6):1346-1349. doi:10.1128/AAC.42.6.1346
  • 24. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med. 1992;116(1):33-43. doi:10.7326/0003-4819-116-1-33
  • 25. Prosty C, Hanula R, Levin Y, Bogoch II, McDonald EG, Lee TC. Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis: a systematic review and meta-analysis. Clin Infect Dis. 2023;76(3):e1302-e1319. doi:10.1093/cid/ciac645
  • 26. Susanto D, Mawuntu A, Warouw F, Wariki W. Effectiveness of non-pyrimethamine-based regimens for toxoplasma encephalitis: a systematic and meta-synthesis study. Asian Pac J Trop Med. 2022;15(3):106-113. doi:10.4103/1995-7645.340572
  • 27. Pellegrino D, Gryschek R, de Oliveira ACP, Marcusso R, Correia A, Vidal JE. Efficacy and safety of trimethoprim-sulfamethoxazole in HIV-infected patients with cerebral toxoplasmosis in Brazil: a single-arm open-label clinical trial. Int J STD AIDS. 2019;30(12):1156-1162. doi:10.1177/0956462419865829
  • 28. Goswami RP, Goswami RP, Rahman M, Ray Y, Tripathi SK. Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting. Int J STD AIDS. 2015;26(12):864-869. doi:10.1177/0956462414560594
  • 29. Mamfaluti T, Firdausa S, Siregar ML, Hasan M, Murdia M. A case report of a successful alternative regimen therapy for toxoplasma encephalitis in AIDS patients. Heliyon. 2023;9(7):e18293. doi:10.1016/j.heliyon.2023.e18293
  • 30. Muchamad GR, Sofro MAU. Lesson learned from delayed definitive treatment of stage 4 HIV patient with cerebral toxoplasmosis: a case report. J Kedokt Diponegoro. 2023;12(1):26-29. doi:10.14710/dmj.v12i1.36701
  • 31. Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34(9):1243-1250. doi:10.1086/339551
  • 32. Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1997;24(3):422-429. doi:10.1093/clinids/24.3.422
  • 33. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. J Clin Epidemiol. 2014;67(1):46-51. doi:10.1016/j.jclinepi.2013.08.003
  • 34. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287
There is no Supplemental content for this article.

How to Cite This

Aurellia, L., Badriyah, R. N., Widya, R. A., Pratama, J. E., Herawati, F., Setiadi, A. A. P., & Gondokesumo, M. E. (2026). A case report Cerebral Toxoplasmosis Therapy in A Patient with Human Immunodeficiency Virus. Jurnal Teknologi Laboratorium, 15(2), 188–194. https://doi.org/10.29238/teknolabjournal.v15i2.494

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].